Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement


Print article Print article
© Marketwire 2012
2012-12-11 21:04:17 -

TUSTIN, CA -- (Marketwire) -- 12/11/12 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement.





The letter received today noted that as of December 10, 2012, the company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the company has regained compliance with NASDAQ Marketplace Rule 5550(a)(2) and the matter is closed.



About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials, focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com : ctt.marketwire.com/?release=964690&id=2380084&type=1& .. ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com : ctt.marketwire.com/?release=964690&id=2380087&type=1& .. .



Add to Digg : digg.com/submit?phase=2&url= www2.marketwire.com/mw/release_html_b1?release_id=964690 Bookmark with del.icio.us : del.icio.us/post?v=4&noui&jump=close&url= www2.marketwire.com/mw/release_html_b1?release_id=964690 Add to Newsvine : www.newsvine.com/_tools/seed&save?u= www2.marketwire.com/mw/release_html_b1?release_id=964690




Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com : docid: 12964690.nitf -->



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser